Events

Biologics, Biosimilars and Diagnostics: IP Challenges for Early Stage Life Sciences Companies

January 15, 2014
Hotel Palomar, 12 Fourth Street, San Francisco, California

Summary

During the 32nd Annual JP Morgan Healthcare Conference week, Goodwin Procter is hosting a client seminar focused on the interplay between patent rights and regulatory exclusivities is particularly important for early stage life sciences companies focused on biologics and diagnostics.

Whether you are beginning the patent protection process or have existing patent rights, please join us for a comprehensive discussion of the various intellectual property and regulatory challenges facing early stage companies in today’s market. Topics to include:

- Patent eligibility and development of patent rights for biologics and diagnostics after Prometheus and Myriad cases
- Regulatory exclusivities for biologics/biosimilars
- Impact of safe harbor exceptions and patent rights on R&D

For more information, or to register for this event, please click here: http://sites.goodwinprocter.vuturevx.com/28/985/landing-pages/blank-registration.asp?sid=73824ba3-5f9c-491a-8b74-c85c7ee46467.